The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Epidemiology of hepatocellular carcinoma in the United States: Where are we? Where do we go?
Open accessAbstract
The incidence of hepatocellular carcinoma (HCC) has almost tripled since the early 1980s in the United States, where it is the fastest rising cause of cancer-related deaths.1 According to population-based Surveillance Epidemiology and End Results registry data, the overall HCC age-adjusted incidence rates for liver and intrahepatic ducts cancer is as high as 8 per 100,000 underlying population in 2010 (Fig. 1) of which at least 6 per 100,000 are related to HCC. Men are at approximately three times higher risk than women. Asian men (i.e., Chinese, Korean, Filipino, and Japanese) have the highest age-adjusted incidence rates. However, the largest proportional increases have occurred among Hispanics followed by blacks and non-Hispanic whites, whereas the lowest proportional increases have occurred among Asians. In contrast to Asians/Pacific Islanders, HCC incidence rates are reported to be higher among Hispanics born in the United States than among foreign-born Hispanics.2 HCC incidence rates have increased in each successive birth cohort born between 1900 and 19593 (Fig. 2). In addition, the age distribution of HCC patients has shifted to younger ages, with the greatest proportional increases among individuals 45-60 years old (Fig. 2). There is a south to north gradient in the incidence and mortality of HCC; southern states, including Texas, Louisiana, and Mississippi, have some of the highest HCC incidence rates in the nation (Fig. 3). In one study, Texas Latinos and, especially, South Texas Latinos had the highest age-adjusted HCC incidence rates (as high as 10.6 per 100,000).4 Time trends (1975-2010) of population-based age-adjusted incidence and mortality rates for liver and intrahepatic bile ducts cancer in the United States. Both sexes and all races are included. State-specific population-based age-adjusted incidence rates for liver and intrahepatic bile ducts cancer. Both sexes and all races are included. Time-trends of HCC by age groups and birth cohorts in the United States. Source: Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-1491. Most HCC risk factors (chronic infection with hepatitis B [HBV] and/or C virus [HCV] and alcoholic liver disease [ALD]) operate by promoting the development of cirrhosis. Exceptions are rare in HCV-related HCC and mostly represent cases with at least bridging hepatic fibrosis.5 Whereas most cases of HBV-related HCC also occur in the background of cirrhosis (as high as 85% in some studies),6 HBV can cause HCC in the absence of advanced fibrosis or cirrhosis. Although there are several mechanisms for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD-NASH)-related HCC conceivably in the presence of mild or no fibrosis,7 there are no systematic studies to confirm or quantify this contention.8 Indirect measures of severity of hepatic fibrosis, such as degree of liver stiffness using elastography, is associated with risk of HCC.9 The risk of developing HCC in patients with cirrhosis varies with the underlying condition. The highest 5-year cumulative risks are observed in HCV cirrhosis (17% in the West and 30% in Japan), hemochromatosis (21%), HBV cirrhosis (10% in the West and 15% in Asia), alcoholic cirrhosis (8%-12%), and biliary cirrhosis (4%).10, 11 Most large studies and consistent data about the clinical course of HBV infection come from Asian countries, where HBV is endemic and vertical transmission is frequent. This pattern is different in areas that have low incidence of HCC (such as the United States), where HBV infection is mostly acquired in adulthood either through sexual or parenteral routes. There have been only a few adequate studies in Europe and North America that determined the incidence of HCC in hepatitis B surface antigen (HBsAg)-positive individuals—most included only small numbers of HBsAg-positive patients. Nevertheless, the summary HCC incidence rate in these regions is approximately 0.02 per 100 person-years in inactive carriers (HBsAg-positive, but with normal levels of alanine aminotransferase [ALT]), 0.3 in subjects with chronic HBV without cirrhosis, and 2.2 in subjects with HBV-related compensated cirrhosis. On the other hand, cohort studies estimated the incidence rates of HCC among subjects with chronic HBV infection in East Asian countries to be 0.2 per 100 person-years in inactive carriers, 0.6 per 100 person-years for those with chronic HBV infection without cirrhosis, and 3.7 per 100 person-years for those with compensated cirrhosis. Several demographic (male sex, older age, Asian or African ancestry, and family history of HCC), viral (higher levels of HBV replication, HBV genotype, longer duration of infection, coinfection with HCV, human immunodeficiency virus [HIV], or hepatitis D virus), and environmental factors (exposure to aflatoxin and heavy intake of alcohol or tobacco) increase HCC risk
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Self-citationHepatocellular carcinoma in cirrhosis: Incidence and risk factors
Fattovich, G., Stroffolini, T., Zagni, I., & Donato, F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.014 · Cited by 2,591
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266
Chang, M.-H., Chen, C.-J., Lai, M.-S., Hsu, H.-M., Wu, T.-C., Kong, M.-S., Liang, D.-C., Shau, W.-Y., & Chen, D.-S. (1997) · New England Journal of Medicine · doi:10.1056/nejm199706263362602 · Cited by 1,883
Altekruse, S. F., McGlynn, K. A., & Reichman, M. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7753 · Cited by 1,694
Davis, G. L., Alter, M. J., El–Serag, H., Poynard, T., & Jennings, L. W. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.09.067 · Cited by 878
Self-citationMorgan, R. L., Baack, B., Smith, B. D., Yartel, A., Pitasi, M., & Falck-Ytter, Y. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-5-201303050-00005 · Cited by 829
El–Serag, H. B., Hampel, H., & Javadi, F. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2005.12.007 · Cited by 826
Self-citationWhite, D. L., Kanwal, F., & El–Serag, H. B. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.10.001 · Cited by 766
Donato, F. (2002) · American Journal of Epidemiology · doi:10.1093/aje/155.4.323 · Cited by 677
Lok, A. S., Seeff, L. B., Morgan, T. R., di Bisceglie, A. M., Sterling, R. K., Curto, T. M., Everson, G. T., Lindsay, K. L., Lee, W. M., Bonkovsky, H. L., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.09.014 · Cited by 651
Moderate Alcohol Intake and Cancer Incidence in Women
Allen, N. E., Beral, V., Casabonne, D., Kan, S. W., Reeves, G. K., Brown, A., Green, J., & Collaborators, O. B. O. T. M. W. S. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn514 · Cited by 600
Associations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular Carcinoma
Yang, H.-I., Yeh, S.-H., Chen, P.-J., Iloeje, U. H., Jen, C.-L., Su, J., Wang, L.-Y., Lu, S.-N., You, S.-L., Chen, D.-S., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn243 · Cited by 580
Paradis, V., Zalinski, S., Chelbi, E., Guedj, N., Degos, F., Vilgrain, V., Bedossa, P., & Belghiti, J. (2009) · Hepatology · doi:10.1002/hep.22734 · Cited by 571
Kao, J., Chen, P., Lai, M., & Chen, D. (2003) · Gastroenterology · doi:10.1053/gast.2003.50053 · Cited by 536
Papatheodoridis, G. V., Lampertico, P., Manolakopoulos, S., & Lok, A. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.02.035 · Cited by 459
Singh, S., Singh, P. P., Singh, A. G., Murad, M. H., & Sanchez, W. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.10.005 · Cited by 452
Characteristics of Patients With Nonalcoholic Steatohepatitis Who Develop Hepatocellular Carcinoma
Yasui, K., Hashimoto, E., Komorizono, Y., Koike, K., Arii, S., Imai, Y., Shima, T., Kanbara, Y., Saibara, T., Mori, T., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.01.023 · Cited by 420
Increasing Prevalence of HCC and Cirrhosis in Patients With Chronic Hepatitis C Virus Infection
Kanwal, F., Hoang, T., Kramer, J. R., Asch, S. M., Goetz, M. B., Zeringue, A., Richardson, P., & El–Serag, H. B. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.12.032 · Cited by 395
Self-citationFoxa1 and Foxa2 Are Essential for Sexual Dimorphism in Liver Cancer
Li, Z., Tuteja, G., Schug, J., & Kaestner, K. H. (2012) · Cell · doi:10.1016/j.cell.2011.11.026 · Cited by 382
Meta‐analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma
SUNG, J. J. Y., TSOI, K. K. F., WONG, V. W. S., LI, K. C. T., & CHAN, H. L. Y. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03816.x · Cited by 370
Singh, S., Fujii, L. L., Murad, M. H., Wang, Z., Asrani, S. K., Ehman, R. L., Kamath, P. S., & Talwalkar, J. A. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.07.034 · Cited by 352
Hepatitis B virus DNA levels and outcomes in chronic hepatitis B # †
Chen, C.-J., Yang, H.-I., & Iloeje, U. H. (2009) · Hepatology · doi:10.1002/hep.22884 · Cited by 346
Population-Attributable Fractions of Risk Factors for Hepatocellular Carcinoma in the United States
Welzel, T. M., Graubard, B. I., Quraishi, S., Zeuzem, S., Davila, J. A., El-Serag, H. B., & McGlynn, K. A. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.160 · Cited by 328
Self-citationDiabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta‐analysis
Wang, P., Kang, D., Cao, W., Wang, Y., & Liu, Z. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1291 · Cited by 310
Smith, B. D., Morgan, R. L., Beckett, G. A., Falck-Ytter, Y., Holtzman, D., & Ward, J. W. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-9-201211060-00529 · Cited by 302
Cirrhosis Is Present in Most Patients With Hepatitis B and Hepatocellular Carcinoma
Yang, J. D., Kim, W. R., Coelho, R., Mettler, T. A., Benson, J. T., Sanderson, S. O., Therneau, T. M., Kim, B., & Roberts, L. R. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.08.019 · Cited by 266
Coffee Reduces Risk for Hepatocellular Carcinoma: An Updated Meta-analysis
Bravi, F., Bosetti, C., Tavani, A., Gallus, S., & La Vecchia, C. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.04.039 · Cited by 253
Zhang, Z.-J., Zheng, Z.-J., Shi, R., Su, Q., Jiang, Q., & Kip, K. E. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1267 · Cited by 241
Public health impact of antiviral therapy for hepatitis C in the United States†
Volk, M. L., Tocco, R., Saini, S., & Lok, A. S. F. (2009) · Hepatology · doi:10.1002/hep.23220 · Cited by 224
Raimondi, S., Bruno, S., Mondelli, M. U., & Maisonneuve, P. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.01.019 · Cited by 224
Shi, J., Zhu, L., Liu, S., & Xie, W.-F. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602333 · Cited by 215
Ni, Y.-H., Chang, M.-H., Wang, K.-J., Hsu, H.-Y., Chen, H.-L., Kao, J.-H., Yeh, S.-H., Jeng, Y.-M., Tsai, K.-S., & Chen, D.-S. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.048 · Cited by 213
Influence of Alcohol on the Progression of Hepatitis C Virus Infection: A Meta-analysis
Hutchinson, S. J., Bird, S. M., & Goldberg, D. J. (2005) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(05)00407-6 · Cited by 208
Arase, Y., Kobayashi, M., Suzuki, F., Suzuki, Y., Kawamura, Y., Akuta, N., Kobayashi, M., Sezaki, H., Saito, S., Hosaka, T., et al. (2013) · Hepatology · doi:10.1002/hep.26087 · Cited by 191
Yu, M.-W., Yang, Y.-C., Yang, S.-Y., Cheng, S.-W., Liaw, Y.-F., Lin, S.-M., & Chen, C.-J. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.21.1644 · Cited by 183
Zoutendijk, R., Reijnders, J. G., Zoulim, F., Brown, A., Mutimer, D. J., Deterding, K., Hofmann, W. P., Petersen, J., Fasano, M., Buti, M., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302024 · Cited by 183
Mata, A. M., González-Diéguez, M.-L., Cadahía, V., Varela, M., Pérez, R., Navascués, C. Á., Sotorríos, N. G., Martínez, M., Rodrigo, L., & Rodríguez, M. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.09.007 · Cited by 174
HIV, Age, and the Severity of Hepatitis C Virus–Related Liver Disease: A Cohort Study
Kirk, G. D., Mehta, S. H., Astemborski, J., Galai, N., Washington, J., Higgins, Y., Balagopal, A., & Thomas, D. L. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-9-201305070-00604 · Cited by 170
Chuang, S.-C., Lee, Y. A., Hashibe, M., Dai, M., Zheng, T., & Boffetta, P. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-1297 · Cited by 149
Yu, M. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.24.2023 · Cited by 148
Yang, Y., Zhao, W., Zhong, Y. ‐., Xia, H., Shen, L., & Zhang, N. (2009) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2009.01070.x · Cited by 146
Gordon, S. C., Lamerato, L. E., Rupp, L. B., Li, J., Holmberg, S. D., Moorman, A. C., Spradling, P. R., Teshale, E. H., Vijayadeva, V., Boscarino, J. A., et al. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.09.062 · Cited by 143
Epidemiology of Hepatocellular Carcinoma in Hispanics in the United States
El‐Serag, H. B., Lau, M., Eschbach, K., Davila, J. A., & Goodwin, J. S. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.18.1983 · Cited by 137
Self-citationCho, L. Y., Yang, J. J., Ko, K., Park, B., Shin, A., Lim, M. K., Oh, J., Park, S., Kim, Y. J., Shin, H., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25321 · Cited by 120
Chang, K.-C., Hung, C., Lu, S.-N., et al. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks269 · Cited by 97
Hassan, M. M., Kaseb, A. O., Etzel, C. J., El‐Serag, H. B., Spitz, M. R., Chang, P., Stemke‐Hale, K., Liu, M., Rashid, A., Shama, M., et al. (2013) · Molecular Carcinogenesis · doi:10.1002/mc.22057 · Cited by 96
Self-citationEvaluation of Abdominal Ultrasonography Mass Screening for Hepatocellular Carcinoma in Taiwan
Yeh, Y., Hu, T., Cho, P.-Y., Chen, H.-H., Yen, A. M.-F., Chen, S. L., Chiu, S. Y., Fann, J. C., Su, W., Fang, Y., et al. (2013) · Hepatology · doi:10.1002/hep.26703 · Cited by 75
Meta‐analysis: oral anti‐viral agents in adults with decompensated hepatitis B virus cirrhosis
Singal, A. K., & Fontana, R. J. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04990.x · Cited by 74
Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma
Donadon, V. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i24.3025 · Cited by 66
Miyake, Y., Kobashi, H., & Yamamoto, K. (2009) · Journal of Gastroenterology · doi:10.1007/s00535-009-0024-z · Cited by 66
Insulin Resistance, Obesity, and Liver Cancer
Farrell, G. C. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.07.040 · Cited by 53
Cheng, J. C., Hsu, C.-Y., Hashem, S. A., & Dawson, L. A. (2012) · Springer eBooks · doi:10.1007/978-3-642-28860-9_16 · Cited by 44
Yeh, S., Chang, C.-F., Shau, W., Chen, Y.-W., Hsu, H., Lee, P., Chen, D., & Chen, P. (2002) · PubMed · Cited by 25
Kanwal, F., Lok, A. S.-F., & El‐Serag, H. B. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.01.007 · Cited by 12
Self-citation
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Burden of liver diseases in the world
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.014 · Cited by 3,783
Global burden of liver disease: 2023 update
Devarbhavi, H., Asrani, S. K., Arab, J. P., Nartey, Y. A., Pose, E., & Kamath, P. S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.017 · Cited by 2,267
Epidemiology of Hepatocellular Carcinoma
McGlynn, K. A., Petrick, J. L., & El‐Serag, H. B. (2021) · Hepatology · doi:10.1002/hep.31288 · Cited by 2,147
Self-citationYounossi, Z., Stepanova, M., Ong, J. P., Jacobson, I. M., Bugianesi, E., Duseja, A., Eguchi, Y., Wong, V. W., Negro, F., Yilmaz, Y., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.05.057 · Cited by 806
Metadata
- Authors
- El-Serag, H. B., & Kanwal, F.
- Venue
- Hepatology
- Published
- 2014-11
- Volume
- 60
- Issue
- 5
- Pages
- 1767-1775
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1600724420
- Cited by
- 646
- References
- 55
- FWCI
- 28.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.